Amicus Therapeutics' Galafold (migalastat) Receives FDA Approval for Fabry Disease in Adult Patients
Shots:
- The approval is based on P-III FACET or Study 011 results assessing Galafold (150mg) in patient with Fabry Disease- evaluating its safety and efficacy
- The FACET or Study 011 resulted in reduction of substrate (KIC GL-3) accumulation in the kidney capillaries
- Galafold (migalastat) 123mg is a novel PO dosage form of alpha Galactosidase A used for Fabry Disease in adults and is approved in the US- EU- Australia- Canada- Israel- Japan- South Korea & Switzerland
Ref: Amicus Therapeutics | Image: Reuters
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com